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E-mail address: simizu@applc.keio.ac.jp (S. SimizuCathepsin V (L2), a lysosomal cysteine protease, is a member of cathepsin family, relating to cancer
invasion and metastasis. Cathepsin V contains two predicted N-glycosylation sites, but it has not
been reported whether cathepsin V is glycosylated or not. In this study, we clariﬁed the role of N-gly-
cosylation of cathepsin V for its functions. We demonstrated that cathepsin V is N-glycosylated at
both Asn221 and Asn292 using mass spectrometry and site-directed mutagenesis. N-glycosylation of
cathepsin V was important for transportation to lysosome, secretion, and activity in HT1080 cells.
These data demonstrated that functions of cathepsin V are controlled by N-glycosylation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction most notably cancer and rheumatoid arthritis, providing usefulGlycosylation is one of the post-translational modiﬁcations, and
is important for protein folding, stability, secretion, and providing
recognition epitopes that activate the innate immune system [1,2].
Protein glycosylation is an enzymatic process which takes place
inside the lumen of the endoplasmic reticulum (ER) and the Golgi
apparatus [3]. In the case of N-linked glycans, more than 30 en-
zymes, located in the cytosol, the ER, and the Golgi apparatus,
are required to generate, attach and process the oligosaccharides
[4,5]. As the nascent glycoproteins enter the ER, a preformed oligo-
saccharide known as the dolicol-phosphate precursor is attached
co-translationally to certain Asn residues that are part of the
consensus sequence Asn-Xaa-Ser/Thr (where Xaa represents any
amino acid except Pro) [1].
The attachment and processing of sugars are not random, but
exquisitely controlled by both glycosyltransferase and three-
dimensional structure of glycoproteins [1]. Changes in protein gly-
cosylation are early indicators of cellular changes in many diseases,chemical Societies. Published by E
B, Coomassie Brilliant Blue;
oplasmic reticulum; MALDI-
ime of ﬂight mass spectrom-
ptide N-glycosidase F; TM,
Kohoku-ku, Yokohama 223-
).diagnostic markers and insights into disease progression and path-
ogenesis [6,7].
Cathepsin V, also known as cathepsin L2, is a cysteine protease,
and a member of the cathepsin family [8,9]. Cathepsins related to
protein degradation mostly are localized in the lysosome, although
some cathepsins are localized in the endosome and the cell surface
[10–12]. Among the lysosomal proteases, cathepsins have espe-
cially major roles. In humans, there are 11 cysteine cathepsins
known at the sequence level, including cathepsins B, C, F, H, K, L,
O, S, V, W, and X. Similar to most other proteases, cathepsins are
synthesized as inactive precursors, and are activated by proteolytic
removal of the N-terminal pro-peptides [12,13]. Cathepsins are
processed to the active forms either by autocatalytic activation at
acidic pH environment or by other proteases-mediated activation.
Cathepsin V was ﬁrst identiﬁed in the thymus and testis [8], and
associated with myasthenia gravis, type 1 diabetes, and neurolog-
ical diseases [14–16]. Cathepsin V also highly expressed in colorec-
tal and breast carcinomas [8]. Human cathepsin V being about 78%
identical with human cathepsin L [8,9], which relate to cancer
progression, cathepsin V also may have important roles in cancer
progression in a similar manner as cathepsin L. It is important to
note that mouse cathepsin L has a higher sequence homology to
human cathepsin V than to human cathepsin L, and mice lack
cathepsin V [17].
Based on the amino acid sequence, human cathepsin V contains
two potential N-glycosylation consensus sequences at positionslsevier B.V. All rights reserved.
3602 Y. Niwa et al. / FEBS Letters 586 (2012) 3601–3607Asn221 and Asn292 residues [8,9]. However, it has not been reported
whether cathepsin V is N-glycosylated, and the biological roles of
N-glycosylation for cathepsin V functions.
In this report, we demonstrated that cathepsin V is N-glycosyl-
ated at both Asn221 and Asn292 in human ﬁbrosarcoma HT1080
cells, and it is important for transportation to lysosome, secretion,
and its enzymatic activity. Our data suggest that glycosylation of
cathepsin V relate to cathepsin V-mediated myasthenia gravis,
type 1 diabetes, neurological diseases, and cancer progression.
2. Materials and methods
2.1. Cell culture
A human ﬁbrosarcoma HT1080 cell line was cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented withA
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HT1080-CTSV-MH cells were lysed and each cell lysate was electrophoresed and immuno
treated with or without 10 lg/ml tunicamycin (TM) for 24 h. Cells were lysed, and each10% (v/v) fetal bovine serum, 200 units/ml penicillin G, 200 mg/l
kanamycin, 600 mg/l L-glutamine, and 2.25 g/l NaHCO3 at 37 C
in a humidiﬁed incubator with 5% CO2.
2.2. Assays for Western blot, plasmid construction, site-directed
mutagenesis, establishment of stable cell lines, puriﬁcation of
recombinant cathepsin V, mass spectrometry, semi-quantitative RT-
PCR, in vitro peptide N-glycosidase F treatment, immunoﬂuorescence,
and measurement of enzyme activity
The protocols used for the Western blot, plasmid construction,
site-directed mutagenesis, establishment of stable cell lines, puriﬁ-
cation of recombinant cathepsin V, mass spectrometry, semi-quan-
titative RT-PCR, in vitro peptide N-glycosidase F treatment,
immunoﬂuorescence, and measurement of enzyme activity are
indicated in Supplementary Materials and Methods [17–20].43
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residues after treatment with PNGase F. (C) Fragment 1 (upper) and Fragment 2 (lower) (see Fig. 2B) were analyzed by MALDI-TOF MS/MS. Observed peaks of these fragments
are indicated b-ions and y-ions. Underlined ‘‘D’’s indicate Asp residues converted from glycosylated Asn residues treated with PNGase F.
Y. Niwa et al. / FEBS Letters 586 (2012) 3601–3607 3603
AB
CBB 
staining 
43
36.5 
28
(kDa) 
Anti-c-myc 
Ab
IB
43
36.5 
28
CTSV-MH
CTSV-MH
CTSV-MH
3604 Y. Niwa et al. / FEBS Letters 586 (2012) 3601–36073. Results
3.1. Glycosylation of cathepsin V
The amino acid sequence of human cathepsin V contains two
predicted N-glycosylation consensus sequence, Asn221 and Asn292
residues (Fig. 1A and 1B). To examine whether cathepsin V is gly-
cosylated, we established C-terminal myc-his6 tagged cathepsin
V-overexpressing HT1080 cells (Fig. 1C). Cells were treated with
tunicamycin, an inhibitor of N-glycosylation [21]. Electrophoresis
of cathepsin V from HT1080-CTSV-MH cells treated with tunica-
mycin revealed a more rapidly migrating form than that from un-
treated cells, as detected by Western blotting (Fig. 1D). Thus, these
data suggest that cathepsin V is N-glycosylated in the cell.CTSV-MH
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Fig. 3. Cathepsin V is glycosylated at both Asn221 and Asn292. (A and B) HT1080-neo,
HT1080-CTSV-MH, HT1080-CTSV-MH/N221Q, HT1080-CTSV-MH/N292Q, and
HT1080-CTSV-MH/2NQ cells were lysed, and aliquots of the cell lysates were
electrophoresed and immunoblotted with anti-c-myc antibody (A). Total RNAs
were isolated from each cell line and semi-quantitative RT-PCR was performed (B).
(C) HT1080-neo, HT1080-CTSV-MH, and HT1080-CTSV-MH/2NQ cells were treated
with the indicated concentrations of tunicamycin (TM) for 24 h. Cells were lysed,
and aliquots of the cell lysates were electrophoresed and immunoblotted with the
indicated antibodies. (D) HT1080-neo, HT1080-CTSV-MH, and HT1080-CTSV-MH/
2NQ cells were lysed, and aliquots of the cell lysates were treated with or without
PNGase F for 3 h. Samples were electrophoresed and immunoblotted with anti-c-
myc antibody. (E) HT1080-neo, HT1080-CTSV-MH, HT1080-CTSV-MH/N221Q
(upper), and HT1080-CTSV-MH/N292Q (lower) cells were treated with the indicated
concentrations of tunicamycin (TM) for 24 h. Cells were lysed, and aliquots of the
cell lysates were electrophoresed and immunoblotted with the indicated
antibodies.3.2. Determination of N-glycosylation sites within cathepsin V
To examine whether cathepsin V is glycosylated, we puriﬁed
recombinant cathepsin V protein from conditioned medium of
HT1080-CTSV-MH cells (Fig. 2A). Puriﬁed cathepsin V was treated
with or without PNGase F, digested with API, and the resulting
mixture of peptides was analyzed by MALDI-TOF MS. Because
PNGase F converts N-glycosylated Asn to Asp residues, appearance
of new peaks signifying Asn221 and Asn292 conversion to Asp
residues were expected. As expected, peaks of fragments were ob-
served at m/z 2,123.0 (Fragment 1) and 2,292.0 (Fragment 2),
respectively suggesting Asn221 and Asn292 conversion to Asp resi-
dues (Fig. 2B). Furthermore, to conﬁrm the sequence of the frag-
ments, the resulting mixture of peptides was analyzed by
MALDI-TOF MS/MS. Detected peaks are indicated in Fig. 2C.
Although a number of peaks from Fragment 1 were difﬁcult to
detect by MS/MS, a few were successfully detected. Peaks from
Fragment 2 corresponded well to the expected values. Thus, these
data suggest that Asn221 and Asn292 residues are N-glycosylated.
To clarify the role of N-glycosylation of cathepsin V for its func-
tions, we constructed several mutant forms of the protein, replac-
ing asparagine residues by glutamine residues. The electrophoretic
migration of cathepsin V prepared from HT1080-CTSV-MH/N221Q,
HT1080-CTSV-MH/N292Q, and HT1080-CTSV-MH/2NQ cells was
slightly faster than that from HT1080-CTSV-MH cells, suggesting
a size reduction of mutant cathepsin V proteins (Fig. 3A). Equal
amount of exogenous cathepsin V in the stable cell lines was con-
ﬁrmed by semi-quantitative RT-PCR (Fig. 3B). Treatment of the
HT1080-CTSV-MH cells with tunicamycin resulted in a size
reduction of cathepsin V, but no size reduction was detected in
HT1080-CTSV-MH/2NQ cells as detected byWestern blotting using
anti-c-myc antibody (Fig. 3C). The molecular size between tunica-
mycin-treated wild-type cathepsin V and 2NQ mutant was the
same, and the molecular size of 2NQ mutant protein was not chan-
ged by the treatment with tunicamycin (Fig. 3C). Furthermore,
treatment of wild-type cathepsin V protein with PNGase F, an
enzyme that removes all types of N-linked oligosaccharides from
the glycoprotein, resulted in a size reduction of cathepsin V, but
no size reduction was detected in 2NQ mutant protein as detected
by Western blotting using anti-c-myc antibody (Fig. 3D). The
molecular size between PNGase F-treated wild-type cathepsin V
and 2NQ mutant was the same, and the molecular size of 2NQ mu-
tant protein was not changed by the treatment with PNGase F
(Fig. 3D). These data also suggest that cathepsin V is N-glycosyl-
ated. Moreover, the molecular size between tunicamycin-treated
wild-type cathepsin V, N221Q,and N292Q mutants were the same,
and the electrophoretic migration of untreated N221Q and N292Q
mutants was slightly faster than that of wild-type cathepsin V
(Fig. 3A and 3E). Taken together, these data indicate that cathepsin
V is N-glycosylated at both Asn221 and Asn292.
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cathepsin V
Because cathepsin V might localize mainly in lysosome in a sim-
ilar manner to other cathepsins, we next observed the intracellular
localization of point-mutated cathepsin V. A dominant localization
in diffused structure, determined as ER (data not shown), inside the
cell was evident for both wild-type and all mutants expressing
cells (Fig. 4A and B). Moreover, wild-type cathepsin V stained with
anti-c-myc antibody was detected in the perinuclear organelles
(Fig. 4A and B). Using LysoTracker (Fig. 4A; lysosome-speciﬁc) or
anti-GRASP65 antibody (Fig. 4B; Golgi apparatus-speciﬁc) showed
that cathepsin V was detected in lysosome but a trace amount of
cathepsin V was localized in the Golgi apparatus. N221Q mutant
was also found to localize in lysosome. A ratio of N221Q mutant
protein localization in the lysosome was decreased compared to
the wild-type cathepsin V. Furthermore, N292Q and 2NQ mutants
could also be detected in the lysosome, though much less apparent
than that of wild-type and N221Q (Fig. 4A and 4B). Thus, N-glyco-
sylation of cathepsin V, especially at Asn292, is important for trans-
porting to lysosome.A
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Fig. 4. Role of N-glycosylation on the intracellular trafﬁcking and secretion of cathepsin
CTSV-MH/N292Q, and HT1080-CTSV-MH/2NQ cells were ﬁxed. Samples were stained wit
GRASP65 antibody (red, B), and the cells were observed by ﬂuorescence microscopy. Area
Bar, 10 lm. (C) HT1080-neo, HT1080-CTSV-MH, HT1080-CTSV-MH/N221Q, HT1080-CTSV
for 24 h, before the cultured media and cell lysates were collected. Samples from th
immunoblotted with anti-c-myc antibody.Since N-glycosylation of cathepsin V was important for intracel-
lular trafﬁcking, we next examined the effect of point-mutation on
secretion of cathepsin V. Amounts of secreted wild-type and
N221Q mutant cathepsin V were approximately same (Fig. 4C).
Concomitant with the localization change ratio at the lysosome,
secretion levels of N292Q and 2NQmutant proteins weredecreased
(Fig. 4C). Thus, N-glycosylation of cathepsin V at Asn292 is impor-
tant for cathepsin V secretion.
3.4. Effect of glycosylation on cathepsin V activity
Finally, we examined the role of glycosylation on the activity of
cathepsin V. To assess the enzymatic activities, recombinant wild-
type and mutants cathepsin V were puriﬁed from conditioned
media of established cells, and amounts of cathepsin V proteins
were estimated by CBB staining (data not shown). Equal amounts
of wild-type and mutants cathepsin V were conﬁrmed by Western
blotting (Fig. 5). Activity of cathepsin V was dose-dependent and
was inhibited above the background level in the presence of
E-64, abroad spectrum inhibitor for cysteine protease, suggesting
detection of cathepsin V activity. In the case of N221Q mutant21Q N292Q 2NQ
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Fig. 5. N-glycosylation at Asn292 is required for cathepsin V activity. HT1080-CTSV-MH, HT1080-CTSV-MH/N221Q, HT1080-CTSV-MH/N292Q, and HT1080-CTSV-MH/2NQ
cells were cultured in serum-free DMEM for 24 h, before the culture media were collected. The obtained cultured media were incubated with Ni–NTA agarose, and the bound
proteins were eluted with 300 mM imidazole. Samples were dialyzed to assay buffer for 3 h. The amount of each protein was evaluated by Western blotting using anti-c-myc
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type cathepsin V (Fig. 5). In a contrasting manner, activities of
N292Q and 2NQ mutant proteins were dramatically decreased
(Fig. 5). Thus, these data suggest that N-glycosylation of cathepsin
V, especially at Asn292, is important for cathepsin V activity.
4. Discussion
Because mice lack cathepsin V gene and human cathepsin V is
more similar to mouse cathepsin L than to human cathepsin L
[17], cathepsin V has been recently suggested as a potential candi-
date in addition to, or instead of, cathepsin L. Human cathepsin L is
N-glycosylated at Asn221 [22], which is conserved in human
cathepsin V, but it is not reported whether cathepsin V is N-glycos-
ylated or not. In this report, using MS and several mutant proteins,
we demonstrated that cathepsin V is N-glycosylated at both Asn221
and Asn292 residues (Figs. 2 and 3). In a previous study, it was
suggested that Asn2 is also potentially N-glycosylated [8]. How-
ever, Asn2 is located in the signal peptide. According to our results,
no size reduction was detected in HT1080-CTSV-MH/2NQ cells
treated with tunicamycin and PNGase F (Fig. 3C and 3D). These re-
sults suggest that Asn2 is not N-glycosylated. It has been reported
that abnormal glycosylation relates to cancer progression, and
cathepsins promote tumor invasion and migration [6,7]. Moreover,
N-glycosylation of cathepsin V could be important for cancer
invasion and migration such as colorectal and breast carcinomas,
which express high levels of cathepsin V [8]. To investigate, we
tried to determine whether endogenous cathepsin V is glycosyl-
ated or not. Although several antibodies purchased were tested,
no antibody could react with endogenous cathepsin V in many cell
lines expressing cathepsin V at mRNA level detected by RT-PCR
(data not shown). Further studies are necessary to determine
whether endogenous cathepsin V is glycosylated and clarify the
relationship between N-glycosylation of cathepsin V and cancer
progression and/or malignancy in human cancer.We showed that cathepsin V is localized in lysosome and se-
creted into the cultured medium (Fig. 4). Analysis of the human
cathepsin V amino acid sequence indicates the presence of a
hydrophobic 17-amino acid region at the N-terminal (Fig. 1A and
Refs. [8,9]), which functions as a signal peptide, directing the pro-
tein to the ER and Golgi apparatus and subsequently transporting
to the lysosome or through the secretory pathway. We observed
that cathepsin V is localized in the lysosome and the cultured med-
ium in HT1080 cells. Furthermore, we demonstrated that N-glyco-
sylation of cathepsin V, especially at Asn292, is important for the
transportation to lysosome and secretion (Fig. 4). Golgi apparatus
accumulations of N292Q and 2NQ proteins were barely observed,
and trace amounts of N292Q and 2NQ proteins were secreted into
the cultured media. These data suggest that the Asn292 residue of
cathepsin V may be a pivotal glycosylation site determinative for
the kinetics of transportation to the lysosome and secretion in
the cells. Interestingly, cathepsin V activity was controlled by
N-glycosylation especially at Asn292 (Fig. 5), and it was strongly
associated with intracellular trafﬁcking and secretion. From the
three-dimensional structure of human cathepsin V [23], both
N-glycosylation sites at positions Asn221 and Asn292 residues were
not close to the active sites (Fig. 1B). It is therefore unlikely that
N-glycosylation at Asn292 could contribute the recognition of its
substrates directly. Thus, inhibition of N-glycosylation at Asn292
may affect its enzyme activity indirectly, such as recognition step
of protein transporting to lysosome or folding to be activated.
We tried to investigate the role of N-glycosylation in cathepsin
V maturation, but we could not detect mature-form cathepsin V in
this study. Usually, cathepsins are synthesized as inactive precur-
sors, and are activated by proteolytic removal of the N-terminal
pro-peptide [12,13]. Cathepsins are processed to the active forms
either by autocatalytic activation at acidic pH or by other prote-
ase-mediated activation. However, our results show that human
cathepsin V may not be processed to the active forms in HT1080
cells, whereas the activity is detected (Figs. 1 and 5). Thus, we
Y. Niwa et al. / FEBS Letters 586 (2012) 3601–3607 3607speculated that N-terminal removal is not required for the activa-
tion of cathepsin V. Because we detected cathepsin V with anti-
c-myc antibody, we could not exclude the possibility that cathep-
sin V is activated by cleavage of its N-terminal after C-terminal
digestion. Further studies are necessary to clarify the activation
mechanism of cathepsin V.
In the cysteine cathepsins, it is ﬁrst report to investigate roles of
N-glycosylation. Because cathepsin V intracellular trafﬁcking,
secretion, and enzymatic activity were controlled by N-glycosyla-
tion, glycosylation of cathepsin V may relate to cathepsin V-medi-
ated myasthenia gravis, type 1 diabetes, and neurological diseases.
Furthermore, glycosylation inhibitors and glycosidase inhibitors
are known to suppress tumor invasion and migration in vitro and
in vivo [24–26]. Our results demonstrate important roles of N-gly-
cosylation in cathepsin V functions in a human tumor cell line.
Additionally, glycosylation of other cysteine cathepsins also may
be important for their inﬂuences on human diseases.
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